Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 3:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 29,011 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disease;Neurological Clear all
Completed Not applicable Interventional

Waking Hypnosis in the Treatment of MS-related Fatigue

NCT04429789
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Active-Alert Hypnosis, Traditional Hypnosis
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 29, 2026, 3:32 PM EDT
Recruiting Phase 1 Interventional

Safety of Cultured Allogeneic Adult Umbilical Cordor Placental Derived Stem Cells Exosomes for Trigeminal Neuralgia

NCT05152368
View directory record Official record
Conditions
Peripheral Neuropathy, Trigeminal Neuralgia
Interventions
cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes
Biological
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Naples, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 29, 2026, 3:32 PM EDT
Completed Not applicable Interventional Results available

Study of the Effect of Individualizing Daytrana Wear-times on Sleep in Children With ADHD

NCT00989950
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, INSOMNIA
Interventions
Daytrana
Drug
Lead sponsor
Cox Health Systems
Other
Eligibility
6 Years to 12 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 29, 2026, 3:32 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

LSFG-SKIN, Laser Speckle Flowgraphy

NCT03660618
View directory record Official record
Conditions
Hypertension, Heart Failure, Vascular Ischemia, Burns, Chemotherapy Effect, Radiation Injuries, Uveitis, Scleritis, Multiple Sclerosis, Autonomic Neuropathy, Stroke, Intracranial Hemorrhages, TIA, Migraine, Headache, Pain
Interventions
laser speckle flowgraphy
Device
Lead sponsor
Randy Kardon
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 29, 2026, 3:32 PM EDT
Recruiting No phase listed Observational

Patterns of Neurodevelopmental Disorders

NCT06213090
View directory record Official record
Conditions
Neurodevelopmental Disorders, Autism Spectrum Disorder, Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infection, Pediatric Acute-Onset Neuropsychiatric Syndrome, Down Syndrome, Epilepsy, Mitochondrial Encephalomyopathies, Cerebral Folate Deficiency
Interventions
Not listed
Lead sponsor
Richard Frye
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 29, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

A Novel Wearable Device to Improve Sleep Quality

NCT05952297
View directory record Official record
Conditions
Insomnia
Interventions
Sleep Wellness Device (BeCurie)
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 29, 2026, 3:32 PM EDT
Completed Not applicable Interventional Results available

Sleep Disruption in New Mothers: An Intervention Trial

NCT01321710
View directory record Official record
Conditions
Pregnancy, Postpartum Period, Sleep Disturbance
Interventions
Sleep hygiene, Dietary information, Acetaminophen
Behavioral · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Oct 29, 2026, 3:32 PM EDT
Enrolling by invitation Phase 2 Interventional

An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis

NCT07459660
View directory record Official record
Conditions
Psychosis Associated With Alzheimer's Disease
Interventions
ML-007C-MA
Drug
Lead sponsor
MapLight Therapeutics
Industry
Eligibility
55 Years to 91 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Anaheim, California • Doral, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 29, 2026, 3:32 PM EDT
Not listed No phase listed Observational

Digital Evaluations and Technologies Enabling Clinical Translation for AD

NCT05385913
View directory record Official record
Conditions
Alzheimer Disease, Early Onset
Interventions
Multivitamin-no intervention
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
65 Years and older
Enrollment
200 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 29, 2026, 3:32 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)

NCT05262023
View directory record Official record
Conditions
Frontotemporal Dementia
Interventions
DNL593, Placebo
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 29, 2026, 3:32 PM EDT
Enrolling by invitation No phase listed Observational

Reverse Shoulder Arthroplasty vs Rotator Cuff Repair for 60+

NCT06848023
View directory record Official record
Conditions
Shoulder Injuries, Shoulder Pain
Interventions
Reverse Total Shoulder Arthroplasty, Rotator Cuff Repair
Procedure
Lead sponsor
Campbell Clinic
Other
Eligibility
60 Years to 95 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 29, 2026, 3:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

NCT06422923
View directory record Official record
Conditions
Epilepsy, Temporal Lobe
Interventions
NRTX-1001
Biological
Lead sponsor
Neurona Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 29, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

Acamprosate in Youth With Fragile X Syndrome

NCT01300923
View directory record Official record
Conditions
Fragile X Syndrome, Autism Spectrum Disorders
Interventions
Acamprosate
Drug
Lead sponsor
Indiana University
Other
Eligibility
5 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 29, 2026, 3:32 PM EDT
Completed Phase 4 Interventional Results available

Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults

NCT00696293
View directory record Official record
Conditions
Major Depressive Disorder, Back Pain, Aged
Interventions
Duloxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 29, 2026, 3:32 PM EDT
Completed Not applicable Interventional

Head and Neck Cancer Survivorship Ototoxicity Screening (SOS)

NCT05789316
View directory record Official record
Conditions
Head and Neck Cancer Survivors, Cancer of the Head and Neck Surviors
Interventions
Ototoxicity Screening Protocol
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 29, 2026, 3:32 PM EDT
Not listed Phase 2 Interventional

Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis

NCT01730716
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Human spinal cord stem cell implantation
Device
Lead sponsor
Neuralstem Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 29, 2026, 3:32 PM EDT
Completed Phase 2 Interventional Results available

PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder

NCT00340704
View directory record Official record
Conditions
Bladder, Neurogenic
Interventions
tamsulosin hydrochloride
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 16 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 29, 2026, 3:32 PM EDT
Completed Not applicable Interventional

Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration

NCT05526404
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Dieta mobile application
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 29, 2026, 3:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

50 Hz Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Parkinson's Disease

NCT00977184
View directory record Official record
Conditions
Parkinson Disease
Interventions
50 HZ Repetitive TMS, Sham rTMS
Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
40 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 27, 2012 · Synced Oct 29, 2026, 3:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

NCT01582152
View directory record Official record
Conditions
Brain Neoplasms, Central Nervous System Neoplasms
Interventions
TPI287, Bevacizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 29, 2026, 3:32 PM EDT
Completed Phase 3 Interventional Results available

Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS

NCT00335452
View directory record Official record
Conditions
Acute Coronary Disease, Angina Unstable
Interventions
Clopidogrel, acetylsalicyclic acid (ASA)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
25,086 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Oct 29, 2026, 3:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery

NCT01592552
View directory record Official record
Conditions
Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS)
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Sherman Oaks, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 29, 2026, 3:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Implementation of Transdx Group for POTS

NCT03185247
View directory record Official record
Conditions
Dysautonomia, Anxiety, Depression
Interventions
Transdiagnostic Group-Based Treatment
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
13 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 29, 2026, 3:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Safety and PK of a Single IM Dose of G03-52-01 vs Placebo in Adult Subjects

NCT04171115
View directory record Official record
Conditions
Healthy
Interventions
G03-52-01, Placebo
Drug
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 29, 2026, 3:32 PM EDT